色综合久久久久8天国,91亚洲人成手机在线观看,免费观看视频18勿进免费观看

N-乙酰-加利車霉素

NMR下載 COA and HPLC MSDS下載
names：
N-Acetyl-Calicheamicin
CAS號：
108212-76-6
MDL Number： MFCD29924715
MF(分子式)： C57H76IN3O22S4 MW(分子量)： 1410.39
EINECS: Reaxys Number:
Pubchem ID:122705998 Brand:BIOFOUNT

N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)是一類高活性抗腫瘤的抗生素。N-乙酰-加利車霉素是一種有效的烯二炔抗腫瘤抗生素。目標：抗菌N-乙酰-卡奇霉素是卡利奇霉素的一種衍生物。Calicheamicin是一種天然存在的疏水性烯二炔抗生素，從放線菌微單孢菌echinospora calichensis中分離出來。加里車霉素不僅可以通過切割游離DNA來干擾生物過程，而且可以通過競爭或調節DNA結構來取代DNA結合蛋白，從而干擾生物過程。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000161-5mg	5mg	>98.0%	￥ 65750.00	￥ 65750.00		2-3天	- +	￥ 0.00
YZM000161-1mg	1mg	>98.0%	￥ 18550.00	￥ 18550.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	N-乙酰-加利車霉素(108212-76-6); N-乙酰-加利車霉素γ1; N-乙酰-加利車霉素γ; N-乙酰-加利車霉素; N-乙酰-γ-卡奇霉素;
英文別名	N-Acetyl-Calicheamicin(108212-76-6);CS-5417;HY-19791; N-Acetyl-Calicheamicin γ1; N-Acetyl-Calicheamicin γ; N-Acetyl-Calicheamicin; N-Acetyl-γ-calicheamicin；
CAS號	108212-76-6
Inchi	InChI=1S/C57H76IN3O22S4/c1-13-61(30(6)62)32-25-76-37(23-36(32)71-7)81-50-45(66)42(27(3)78-55(50)80-35-18-16-14-15-17-20-57(70)24-34(64)43(59-56(69)75-11)40(35)31(57)19-21-85-87-84-12)60-83-38-22-33(63)52(29(5)77-38)86-53(68)39-26(2)41(58)48(51(74-10)47(39)72-8)82-54-46(67)49(73-9)44(65)28(4)79-54/h14-15,19,27-29,32-33,35-38,42,44-46,49-50,52,54-55,60,63,65-67,70H,13,21-25H2,1-12H3,(H,59,69)/b15-14-,31-19+/t27-,28+,29-,32+,33+,35+,36+,37+,38+,42-,44+,45+,46-,49-,50-,52-,54+,55+,57+/m1/s1
InchiKey	WPDOZYZAJKUVRZ-IOCYQWGVSA-N
分子式 Formula	C57H76IN3O22S4
分子量 Molecular Weight	1410.39
溶解度Solubility
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:N-乙酰-加利車霉素試劑,N-乙酰-加利車霉素雜質,N-乙酰-加利車霉素合成,N-乙酰-加利車霉素中間體,N-乙酰-加利車霉素密度,N-乙酰-加利車霉素溶解度,N-乙酰-加利車霉素旋光度,N-乙酰-加利車霉素購買,

產品說明	N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)是一種有效的烯二炔抗腫瘤抗生素。
Introduction	N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin) is a potent enediyne antitumor antibiotic.
Application1	N-乙酰基加利車霉素是一種有效的烯二炔抗腫瘤抗生素，可用于抗體-藥物結合（ADC）。
Application2
Application3

N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)藥理學：

1、N-乙酰-加利車霉素是一種有效的烯二炔抗腫瘤抗生素。目標：抗菌N-乙酰-卡奇霉素是卡利奇霉素的一種衍生物。Calicheamicin是一種天然存在的疏水性烯二炔抗生素，從放線菌微單孢菌echinospora calichensis中分離出來。加里車霉素不僅可以通過切割游離DNA來干擾生物過程，而且可以通過競爭或調節DNA結構來取代DNA結合蛋白，從而干擾生物過程。

2、N-乙酰-卡利奇霉素是卡利奇霉素的衍生物，是烯二炔抗腫瘤抗生素的一種，可能是潛在的細胞毒性DNA結合劑。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)危害標識：

象形圖


信號	Danger
GHS危險說明	Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
	H300 (50%): Fatal if swallowed [Danger Acute toxicity, oral]
	H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]
	H310 (50%): Fatal in contact with skin [Danger Acute toxicity, dermal]
	H315 (50%): Causes skin irritation [Warning Skin corrosion/irritation]
	H319 (50%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
	H330 (50%): Fatal if inhaled [Danger Acute toxicity, inhalation]
	H335 (50%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
	H341 (50%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]
	H351 (50%): Suspected of causing cancer [Warning Carcinogenicity]
	H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
	H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]
	Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范說明代碼	P201, P202, P260, P261, P262, P264, P270, P271, P280, P281, P284, P301+P310, P301+P312, P302+P350, P302+P352, P304+P340, P305+P351+P338, P308+P313, P310, P312, P314, P320, P321, P322, P330, P332+P313, P337+P313, P361, P362, P363, P403+P233, P405, and P501
防范說明代碼	(The corresponding statement to each P-code can be found at the GHS Classification page.)

Stasi R, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 2008 Feb;34(1):49-60.

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia PMID 17942233; Cancer treatment reviews 2008 Feb; 34(1):49-60 (Review Article) Name matches: 1,2-dimethyl-hydrazine dichloride n-acetyl

N-乙酰-加利車霉素(108212-76-6,N-Acetyl-Calicheamicin)參考文獻：

1.Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Stasi R;Evangelista ML;Buccisano F;Venditti A;Amadori S Cancer Treat Rev. 2008 Feb;34(1):49-60. Epub 2007 Oct 17.

Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti-CD33 antibody (hP67.6) linked to N-acetyl-calicheamicin 1,2-dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration in May 2000 as single-agent therapy for first recurrence of acute myeloid leukemia (AML) in patients over the age of 60 years who are unfit for conventional cytotoxic therapy. In this setting, it produces a complete response (CR) rate of 13%, with another 13% achieving CR with inadequate platelet recovery (CRp). The most common adverse effects associated with GO are infusion-related reactions and myelosuppression. GO monotherapy at the dose of 9 mg/m(2) is complicated with hepatic veno-occlusive disease in approximately 5% of cases, particularly prior to or following stem cell transplantation. Attenuated doses of GO or fractionated doses appear to be equally effective and better tolerated. GO has shown remarkable activity in acute promyelocytic leukemia, particularly for the elimination of minimal residual disease. Combinations of GO with chemotherapy as induction or post-remission therapy are promising, and phase III trials are ongoing.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開